Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 28;15(8):2032.
doi: 10.3390/pharmaceutics15082032.

The Potential of the Nose-to-Brain Delivery of PACAP for the Treatment of Neuronal Disease

Asma Cherait  1   2   3 , William A Banks  4   5 , David Vaudry  1   6
Affiliations
Review

The Potential of the Nose-to-Brain Delivery of PACAP for the Treatment of Neuronal Disease

Asma Cherait et al. Pharmaceutics. .

Abstract

Research on the neuroprotective effect of pituitary adenylate cyclase-activating polypeptide (PACAP) and its use as a therapeutic agent has grown over the past 30 years. Both in vitro and in vivo experiments have shown that PACAP exerts a strong neuroprotective effect in many central and peripheral neuronal diseases. Various delivery routes have been employed from intravenous (IV) injections to intracerebroventricular (ICV) administration, leading either to systemic or topical delivery of the peptide. Over the last decade, a growing interest in the use of intranasal (IN) administration of PACAP and other therapeutic agents has emerged as an alternative delivery route to target the brain. The aim of this review is to summarize the findings on the neuroprotective effect of PACAP and to discuss how the IN administration of PACAP could contribute to target the effects of this pleiotropic peptide.

Keywords: apoptosis; cerebral plasticity; inflammation; intranasal delivery route; neuronal diseases; neuroprotection; pituitary adenylate cyclase-activating polypeptide; redox state.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Multi-neuroprotective mechanisms of PACAP administrated intranasally in neurodegenerative disease (ND). The figure was created with BioRender.com and Microsoft PowerPoint 2021.
Figure 2
Figure 2
Summary of the advantages using nose-to-brain PACAP administration in the clinic. The figure was created using BioRender.com and Microsoft PowerPoint 2021.
Figure 3
Figure 3
Summary of the difficulties associated with the use of nose-to-brain (NtB) PACAP administration in clinic. The figure was created using Microsoft PowerPoint 2021.
Figure 4
Figure 4
Arterial blood pressure measurement (mmHg) before and after nose-to-brain (NtB) delivery of PACAP (n = 5) and NaCl (n = 4) in mice. All animals were treated with a single NtB administration of 10 µL of PACAP (1 µg/µL) or Nacl (0.9%). The figure was created using GraphPad Prism 6. Statistical analysis of the results revealed no significant differences.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 1989;164:567–574. doi: 10.1016/0006-291X(89)91757-9. - DOI - PubMed
    1. Vaudry D., Falluel-Morel A., Bourgault S., Basille M., Burel D., Wurtz O., Fournier A., Chow B.K., Hashimoto H., Galas L., et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 2009;61:283–357. doi: 10.1124/pr.109.001370. - DOI - PubMed
    1. Yang R., Jiang X., Ji R., Meng L., Liu F., Chen X., Xin Y. Therapeutic potential of PACAP for neurodegenerative diseases. Cell. Mol. Biol. Lett. 2015;20:265–278. doi: 10.1515/cmble-2015-0008. - DOI - PubMed
    1. Meredith M.E., Salameh T.S., Banks W.A. Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases. AAPS J. 2015;17:780–787. doi: 10.1208/s12248-015-9719-7. - DOI - PMC - PubMed
    1. Arimura A., Somogyvari-Vigh A., Miyata A., Mizuno K., Coy D., Kitada C. Tissue Distribution of PACAP as Determined by RIA: Highly Abundant in the Rat Brain and Testes. Endocrinology. 1991;129:2787–2789. doi: 10.1210/endo-129-5-2787. - DOI - PubMed

LinkOut - more resources